PHARVAT is a European Commission (EC) Seventh Framework Programme (FP7) funded project aiming to generate a harmonised procedure to permit pre-clinical selection of vaccine adjuvants. The project is running for a two year period and was initiated in November 2009 with an overall budget of € 300 000.
MultiMalVax call for the conduct of a vaccine clinical trial to evaluate the mosquito-stage component of this multi-stage malaria vaccine.
The MultiMalVax CALL is for a suitable European clinical trial site for the conduct of a phase I clinical trial to assess the safety, immunogenicity and ex-vivo efficacy of simian adenovirus (ChAd63) and Modified Vaccinia Ankara (MVA) vectors expressing mosquito stage Plasmodium falciparum antigens. This clinical trial will start in January 2015, enrol 24 volunteers, and should be conducted within 12 months. University of Oxford will act as sponsor of the clinical trial.